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Summary
Background. Chronic liver disease has been shown to cause
bone osteometabolic disease giving rise to osteoporosis and
osteomalacia.
Aim of this study was to evaluate bone mineral density (BMD)
and bone metabolism markers in a selected series of male pa-
tients living in the same geographical area of Southern Italy,
affected only by viral, non-advanced chronic liver disease, as
compared to a randomly selected control group from the
same geographical area.
Patients ans Methods. Twentyfive male patients affected by
biopsy-proven chronic hepatitis or liver cirrhosis only in
Child’s A class, virus-related, were selected in a one year peri-
od. Thirthy healthy male volunteers, living in the same geo-
graphical area, age, and BMI-matched, were examined as con-
trol group. 
Bone mineral density (BMD) was measured at lumbar spine
(L1-L4) and at proximal femur of non dominant leg by Dual-En-
ergy X-ray Absorptiometry (DEXA) using a Hologic QDR 1000
densitometer. Biochemical tests of liver function and bone
metabolism in patients and controls were carried out after an
overnight fast.
R e s u l t s . BMD was reduced in 16 (64%) out of 25 patients: 5
patients (20%) could be classified as osteoporotic and 11 pa-
tients (44%) osteopenic on the basis of at least one measure-
ment. Mean BMD values for lumbar spine and femoral neck
were significantly decreased in patients in comparison to the
controls. Using multiple linear regression analysis, no correla-
tion was found between BMD and the biochemical and func-
tional variables studied.
Our patients did not show any difference, as compared to con-
trols, in bone remodelling markers as serum PTH, 25-OHD,
calcium and sexual hormones, as well as urinary hydroxypro-
line. 
Conclusions. Our data, obtained on the basis of severe inclu-
sion criteria, suggest that liver disease “per se” indipendently
on its severity and lasting, can reduce the bone mass. There-
fore more attention has to be paid to bone metabolism in liver
patients. 
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Introduction
Metabolic bone disease is a complication of chronic liver dis-
ease (CLD) and is well known as “hepatic osteodistrophy” (1,
2). Osteoporosis accounts for the majority of cases, whereas
osteomalacia is rare in the absence of advanced liver disease
and severe malabsorption (3). The prevalence is the same in
men and women (4), however the published prevalence of os-
teoporosis considerably differs and ranges from 20% to 100%,
depending on patients selection and different diagnostic criteria
(3-5). Many reports are referred to a broad spectrum of liver
disease of different aetiology and severity: in patients with ad-
vanced liver disease candidates for or treated with orthotopic
liver transplantation, osteoporosis is prevalent and contributes
to a major source of morbidity preceding and following trans-
plantation (6, 7). Nevertheless, little is known about the preva-
lence among patients with non-advanced liver disease. The ae-
tiology and pathogenesis of osteoporosis in these patients also
remain undefined, even though its histology is quite similar to
post-menopausal and age-related bone loss, affecting trabecu-
lar bone more rapidly than cortical bone (8, 9). Finally, there is
controversy about risk factors for osteoporosis in CLD: liver cir-
rhosis, cholestasis, hypogonadism, corticosteroid or immuno-
suppressive treatment, alcohol consumption, malnutrition and
malabsorption, sex, physical activity, subnormal vitamin D lev-
els and/or vitamin D receptor genotype, insulin growth factor 1
(IGF-1) deficiency, as well as country and nationality are all re-
ported factors affecting bone metabolism (3-5, 8-11).
However, whether non-advanced liver disease “per se” could
be a risk factor for osteoporosis still remains uncertain; more-
over there are few reports about the effects of viral liver dis-
ease on bone turnover (8).
Aim of this study was to evaluate bone mineral density (BMD)
and bone metabolism markers in a selected series of male pa-
tients living in the same geographical area of Southern Italy, af-
fected only by viral, non-advanced chronic liver disease, as
compared to a randomly selected control group from the same
geographical area.
Patients and methods
In a one year period we studied 98 liver patients consecutively
admitted to the III Department of Internal Medicine, Federico II
University, Naples, Italy. Among them we selected 25 patients
affected by biopsy-proven chronic hepatitis or liver cirrhosis,
virus-related, according to the following inclusion criteria: male
sex, age < 60 years, body mass index (BMI) from 20 to 30
k g / m2, normal physical activity, biopsy-proven liver cirrhosis
only in Child’s A class (12, 13), virus-related.
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All patients lived in the same geographical area from Southern
Italy. Their diet was a tipical mixed, mediterranean diet, con-
taining milk and cheese products, without alcohol intake; only
five patients consumed less than 20 g of alcohol three or four
times a week. Information about dietary habits and alcohol in-
take were carefully obtained from a food frequency question-
naire.
Exclusion criteria were: female sex, age > 60 years, alcohol
abuse, drug addiction, obesity, previous bone fractures or his-
tory of recent immobilization, autoimmune, endocrinological or
rheumatological diseases, treatment with corticosteroids, di-
uretics, drugs affecting bone metabolism or interferon for more
than three months over the past three years. Advanced liver
cirrhosis (B or C Child’s class), hepatocellular carcinoma, pri-
mary biliary cirrhosis, cholestatic liver diseases, genetic he-
mochromatosis were also considered exclusion criteria.
The selected patients had positive serological markers for viral
hepatitis (2 for hepatitis B virus and 23 for hepatitis C virus)
and biopsy-proven diagnosis of chronic liver disease: 12 pa-
tients were affected by chronic hepatitis and 13 patients by liv-
er cirrhosis, A Child’s class. Liver function was well preserved
and renal function was normal in all patients. None exhibited
indices of cholestasis nor experienced previous decompensa-
tion of cirrhosis.
Thirthy healthy male volunteers, living in the same geographi-
cal area, age, and BMI-matched, were also examined as con-
trol group.
All patients and controls received information about the study
and gave their informed consent to participate.
Bone mineral density (BMD) was measured at lumbar spine
(L1-L4) and at proximal femur of non dominant leg by Dual-En-
ergy X-ray Absorptiometry (DEXA) using a Hologic QDR 1000
densitometer.
Osteoporosis was defined in analogy with the World Health Or-
ganization criteria for women (14). Individual BMD values are
expressed as gr/cm2 and T- and Z-score. Quality control was
maintained by daily scanning of an anthropomorphic spine
phantom. The coefficient of variation for the DEXA technique
was less than 1% for the lumbar spine (LS) and 1.5% for the
femoral neck (FN). The reference population adopted in this
study was the international pooled sample provided by the
manifacturer; their data, however, did not differ significantly for
those obtained on a local sample in a study performed when
the device was set up (15).
Biochemical tests of liver function and bone metabolism in pa-
tients and controls were carried out after an overnight fast. Bio-
chemical liver function tests and serum calcium, inorganic
phosphate, and magnesium were measured with an automatic
technique. Serum was assayed using commercially available
kits for intact Parathyroid hormone (PTH), (IRMA, Incstar Cor-
poration), 25-hydroxyvitamin D (25-OHD), (RIA Incstar Corpo-
ration), IGF-1, (RIA, Nichols Institute, San Juan Capistrano,
CA, USA), bone isoenzyme alkaline phosphatase (b-Ap) as a
marker of bone formation (Tandem-T, Ostase, IRMA, Hybritech
Europe, Liege, Belgium), Follicle Stimulating Hormone (FSH),
Luteinizing Hormone (LH), (RIA, Biodata, Serono Diagnostics,
Italy), Prolactin (HPRL), Oestrogen, Progesterone, 17-OH-
Progesterone, Delta-4-Androstenedione, Testosterone (RIA,
Diagnostics Products Corporation, Los Angeles, CA, USA),
Ad enocorticotropic hormone (ACTH), Cortisol, Aldosterone,
complete Thyroid Hormones and antibodies profile (FT3, FT4,
T3, T4, TSH, Tg, TgAb, TPOAb), (RIA, Sorin Biomedica,
Saluggia, Italy).
Urine was analyzed for calcium (automatic absorption spec-
trophotometry) and creatinine (standard automated tech-
niques). Urinary hydroxyproline, as a marker of bone resorp-
tion, was measured with a commercial Kit (OHP Biolab, Italy)
and urinary excretion was expressed in terms of urinary creati-
nine as the ratio of hydroxyproline to creatinine. 
Statistical analysis: results were expressed as means ± SD.
Student’s unpaired t-test was used to compare means between
he groups. The non parametric Mann-Whitney U test was
used when Wik-Shapiro test was not consistent with the
Gaussian distribution of the data. Linear multiple regression
analysis (using as covariates age and BMI) was used to evalu-
ate the determinants of bone mass.
Significance was retained for p < 0.05.
Results
Clinical and laboratory data of patients and controls are report-
ed in Table I.
BMD was reduced in 16 (64%) out of 25 patients: 5 patients
(20%) could be classified as osteoporotic and 11 patients
(44%) osteopenic on the basis of at least one measurement.
Table II reports mean BMD values for lumbar spine (LS) and
femoral neck (FN) in patients and controls, showing a de-
creased BMD in patients in both sides of measurements even if
only for the LS it reaches the significance.
In order to compare the BMD of our patients with reference
population data we calculated the 95% CI of the mean Z-score
at the LS and at the FN. Data showed that the mean Z-score at
LS but not at FN among liver patients was significantly lower as
compared to the age- and sex-matched general population
(lumbar spine mean Z-score 95% CI = -1.06 to -0.920; femoral
eck mean Z-score 95% CI = -0.54 to + 0.53).
Using multiple linear regression analysis we investigated the
r lationship between BMD (gr/cm2) and the variables consid-
ered, including the time of detection of abnormal tests of liver
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Table I - Clinical features and liver function laboratory tests.
Patients (25) Controls (30)
Age 50.4 ± 8.4 51.2 ± 3
BMIkg/m2 26.4 ± 4.6 26.2 ± 3.1
Albumin (g/dl) 4.0 ± 0.5 4.2 ± 0.3
GGT (U/L) 72 ± 11 30 ± 8
Prothrombin time (%) 79 ± 9 98 ± 2
AST (U/L) 90 ± 12 23 ± 6
ALT (U/L) 85 ± 10 25 ± 5
Total bilirubin (mg/dl) 0.7 ± 0.4 0.6 ± 0.4
Alkaline phosphatase (U/L) 155 ± 11 150 ± 7
Table II - BMD in liver patients and controls.
Mean values Patients Controls
Lumbar Spine (L1-L4)
BMD (gr/cm2) 0.992 ± 0.18 1.11 ±
0.08*
Femoral neck
BMD (gr/cm2) 0.858 ± 0.05 0.849 ± 0.15
* P = 0.0254.
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function. No correlation was found between BMD and the vari-
ables studied. 
Biochemical tests of bone remodelling metabolism and hor-
monal profiles did not differ in the two groups.
Discussion
Recently the medical community got to acknowledge that, al-
though not as relevant as in women, male osteoporosis is an
epidemiologically relevant feature of the disease and one out of
three osteoporosis fractures occurs in the male population (16).
Aim of this study was to evaluate bone mineral density and
bone metabolism markers in a selected series of male patients
affected only by viral, non-advanced chronic liver disease. This
illness is known to affect patients metabolism, possibly leading
to hypermetabolism (17) affecting also the bone turnover. The
eccessive bone turnover activity can lead to an alteration of
bone trabeculae, and to their perforation. This fact leads to a
damage of bone micro-architecture and, consequently, to the
reduction of proper mechanical characteristics of the bone seg-
ment and to increased risk of fracture (18).
The present study shows that viral chronic liver disease in man
is associated with reduced bone mineral density. In fact BMD
at LS was significantly lower in liver patients as compared to
controls (p<0.05) and BMD at FN showed a trend to reduction
even though the difference between patients and controls was
not statistically significant (Table I). Data are obtained using
two different groups of controls: 1) age, BMI-matched healthy
volunteers, 2) population-based reference values. 
Osteoporosis has been described in patiens treated with ortho-
topic liver transplantation (6), as well as in subjects affected by
advanced liver cirrhosis, primary biliary cirrhosis, cholestatic or
alcoholic liver diseases, hemochromatosis (1-5) and in corti-
costeroid treated patients (1-3, 19), but little is known about
bone mineral density in viral non advanced liver disease. 
A recent paper on this issue (8) reported in viral cirrhosis in
men a high prevalence of osteoporosis suggesting that it is a
major cause of reduced bone mineral density in men. However,
in this study three heterogeneous groups of patients, aged 38-
74, affected by different severity of liver disease, according to
Child’s classification (12) and Pugh’s score (13) were studied:
a significant correlation between BMD at lumbar spine and
severity of liver disease was found. An advanced age and a
more severe liver disease could both affect the results, there-
fore, in the present study we examined 25 male patients select-
ed on the basis of very restricted criteria: it was a homoge-
neous group, without confounding factor affecting bone metab-
olism, B and C Child’s classes of liver cirrhosis and subsets
aged > 60 years were excluded. 
Previous papers reported low serum levels of PTH, 25-OHD,
and calcium in advanced liver cirrhosis graded as Child’s C
class (5, 8, 20). In contrast we did not find any difference be-
tween patients and controls for all biochemical parameters of
bone metabolism. These discrepancies may be explained by
patient selection and different pathogenetic mechanisms. In
fact, the pathogenesis of reduced bone density in chronic liver
disease remains not clear. Reduced osteoblastic function with
diminished bone formation has been suggested as the main
factor responsible for osteoporosis in alcoholic liver cirrhosis:
it is defined “low turnover osteoporosis” and low serum con-
centrations of IGF-1 are associated with this condition (8, 9).
In contrast, a “high turnover osteoporosis” is characterized by
normal or reduced bone formation coupled with increased re-
sorption. In this case synthesis of matrix and its mineralization
are normal, but osteoblasts are unable to fill the numerous re-
sorption cavities. “High turnover osteoporosis” has been main-
ly reported in patients with chronic cholestatic liver disease as
primary sclerosing cholangitis, and primary biliary cirrhosis (4,
8, 9).
In our patients serum levels of IGF-1 are normal since they are
affected by non advanced liver disease and it is known that
IGF-1 levels are related to the severity of liver disease (8).
Our patients did not show any difference, as compared to con-
trols, in bone remodelling markers as serum PTH, 25-OHD,
calcium and sexual hormones, as well as urinary hydroxypro-
line. 
Neverthless, a high prevalence of osteoporosis and osteopenia
was found in our selected group of male patients and bone
mass reduction was more severe at LS (trabecular bone) than
at FN (cortical and trabecular bone) in keeping with the above
mentioned papers (8-11), probably because the rate of
turnover in cortical bone is much lower than in trabecular bone. 
I  conclusion our data, obtained on the basis of severe inclu-
sion criteria, excluding confounding factor affecting bone me-
tabolism, suggest that liver disease “per se” indipendently on
its severity and lasting, can reduce the bone mass.
The exclusion of female sex and advanced age, and the study
of a very homogeneous group of male patients not alcohol con-
sumers, never treated with steroids or drugs affecting bone
mass, without clinical or laboratory signs of cholestasis suggest
that osteoporosis is a frequent finding in males with non ad-
vanced viral liver disease and that more attention has to be
paid to bone metabolism in liver patients. 
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